Polydex Pharmaceuticals Valuation
Is POLX.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of POLX.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate POLX.F's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate POLX.F's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for POLX.F?
Key metric: As POLX.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is POLX.F's PS Ratio? | |
|---|---|
| PS Ratio | 1.4x |
| Sales | US$4.74m |
| Market Cap | US$6.82m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.4x |
| Enterprise Value/EBITDA | -16.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does POLX.F's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.5x | ||
EDXC Endexx | 1.2x | n/a | US$6.0m |
AYTU Aytu BioPharma | 0.1x | -4.6% | US$9.3m |
MSTH Mystic Holdings | 0.3x | n/a | US$5.7m |
SNOA Sonoma Pharmaceuticals | 0.3x | 25.3% | US$3.9m |
POLX.F Polydex Pharmaceuticals | 1.4x | n/a | US$6.8m |
Price-To-Sales vs Peers: POLX.F is good value based on its Price-To-Sales Ratio (1.4x) compared to the peer average (11.8x).
Price to Sales Ratio vs Industry
How does POLX.F's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Sales vs Industry: POLX.F is good value based on its Price-To-Sales Ratio (1.4x) compared to the US Pharmaceuticals industry average (2.9x).
Price to Sales Ratio vs Fair Ratio
What is POLX.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.4x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate POLX.F's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Kiniksa Pharmaceuticals International
US$1.5b
A biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide.
KNSA
US$21.28
7D
-0.05%
1Y
33.2%
Spectrum Pharmaceuticals
US$209.9m
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.
SPPI
US$1.03
7D
5.3%
1Y
17.0%
Teva Pharmaceutical Industries
US$19.4b
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
TEVA
US$17.12
7D
4.2%
1Y
79.3%